{"url_path":"/sec/ctxr/8-k/2026-06-01/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1506251/0001213900-26-063531-index.html","accession_number":"0001213900-26-063531","cik":"0001506251","ticker":"CTXR","issuer_name":"Citius Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1506251/0001213900-26-063531-index.html","primary_entity_key":"0001506251","primary_entity_name":"Citius Pharmaceuticals, Inc."},"word_count":298,"has_tables":true,"body_markdown":"false\n0001506251\n\n0001506251\n\n2026-06-01\n2026-06-01\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\nCURRENT REPORT\n\nPursuant to Section 13 or 15(d) of\n\nthe Securities Exchange Act of 1934\n\n \n\nDate of Report (Date of earliest event reported)\n**June 1, 2026**\n\n \n\n**Citius Pharmaceuticals, Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Nevada**\n\n(State or other jurisdiction of incorporation)\n\n \n\n**001-38174**\n \n**27-3425913**\n\n(Commission File Number)\n \n(IRS Employer\n\nIdentification No.)\n\n \n\n**11 Commerce Drive, 1st Floor,**\n\n**Cranford, NJ**\n\n \n**07016**\n\n(Address of principal executive offices)\n \n(Zip Code)\n\n \n\nRegistrant’s telephone number, including area code\n**(908) 967-6677**\n\n \n\nCheck the appropriate box\nbelow if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following\nprovisions:\n\n \n\n☐\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n \n**Trading Symbol(s)**\n \n**Name of each exchange on which registered**\n\nCommon stock, $0.001 par value\n \nCTXR\n \nThe Nasdaq Capital Market\n\n \n\nIndicate by check mark whether\nthe registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule\n12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company,\nindicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial\naccounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}